Matthew Albert
Vice President - Translational Sciences & Early Clinical Development Octant
Seminars
Thursday 30th April 2026
Pan-Variant GPCR Correction: Engineering an Orthosteric Small Molecule to Reverse Rhodopsin Misfolding and ER Stress in adRP
3:45 pm
- A first-in-disease small-molecule orthosteric corrector of Rhodopsin that restores folding, trafficking, and reduces toxic ER stress across diverse adRP variants
- Using deep mutational scanning to map variant-level misfolding and define a pan-variant correction profile that enables quantitative, mechanism-based patient stratification
- Establishing a genetics-driven precision ophthalmology framework that integrates variant-resolved pharmacology, structural biomarkers, and PK/PD modeling to guide clinical development
